Recent work in our laboratory suggests that the greater portion of the enhancement in cardiac function seen in endurance-trained athletes is simply a passive response to their higher blood volume (BV). We speculated that an additional increase in plasma volume (PVexp), (500 ml of 6% dextran) would lead to further enhancements in their endurance performance, ˙VO2 max and cardiac function. Therefore, nine highly trained endurance cyclists(˙VO2 max ≥ 65 ml·kg-1·min-1) were studied employing a double blind, cross-over design; i) before PVexp(Ctrl 1), ii) following sham PVexp (Sham), iii) following restoration to normocythemia (Ctrl 2), iv) after PVexp, andv) upon re-establishment of control haematologic levels (Ctrl 3). PVexp resulted in a 547 ± 61 ml increase in BV (p < 0.05). The consequent hemodilution resulted in a reduction of 6% in both the oxygen-carrying capacity and oxygen content of blood. There were no significant differences in endurance performance or ˙VO2 max among conditions. Following PVexp, left ventricular ejection time was significantly increased but there were no significant changes in left ventricular ejection rate, diastolic filling time or diastolic filling rate. As well, PVexp had no significant effect on arterial blood pressure or total peripheral resistance. Maximal cardiac output (Qmax) and maximal stroke volume (SVmax) were significantly higher following PVexp (3.2% and 3.4% respectively), which was sufficient to offset the hemodilution effects of PVexp and allow˙VO2 max and endurance performance to remain unchanged. These results suggest that in endurance-trained athletes who already have a high BV, an additional increase in PV will not result in a sufficient increase in SVmax and Qmax to overcome the hemodilution effects of acute Pvexp, resulting in no further enhancements in endurance performance, ˙VO2 max or cardiac function. Thus, endurance athletes may be at an optimal BV which is at the limits of their diastolic reserve capacity.
Read full abstract